PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL

Johnson & Johnson’s BTK inhibitor Imbruvica plus AbbVie and Roche’s Vencylxto demonstrated superiority over Gazyva plus chemotherapy in a new Phase III study.
In elderly and unfit patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), fixed-duration Imbruvica (ibrutinib) plus Venclyxto (venetoclax) had superior progression free survival (PFS) compared to Gazyva (Obinutuzumab) plus chlorambucil.
The improvement in PFS was also found to favour Imbruvica/Venclyxto across predefined subgroups, including older patients and patients with higher comorbidity scores.
Median PFS was not reached for Imbruvica/Venclyxto at a median follow-up of 27.7 months – in the Gazyva/chemotherapy group it was 21 months.
At three months after the end of treatment, the undetectable minimal residual disease (uMRD) was also ‘significantly higher’ for the Imbruvica/Venclyxto group versus Gazyva plus chemotherapy in both bone marrow and peripheral blood.
In addition, complete response rates – including CR with incomplete haematologic recovery – were significantly higher for Imbruvica/Venclyxto versus Gazyva/chemotherapy.
“Imbruvica and Venclyxto have complementary mechanisms of action, and the promising results from the CAPTIVATE and GLOW studies show that this all-oral regimen that many patients can take at home may provide an effective, flexible treatment option for patients with CLL/SLL seeking a fixed-duration therapy,” said Craig Tendler, vice president, late development and global medical affairs, oncology, Janssen Research & Development.
Last September, the European Commission (EC) expanded the marketing authorisation for Imbruvica to include treatment-naïve patients with CLL.
This decision was based on data from the Phase III E1912 study, which showed that previously untreated adults aged 70 years or younger given the drug plus rituximab lived longer without disease progression than those treated with the established chemo-immunotherapy regimen fludarabine, cyclophosphamide and rituximab (FCR).

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026